Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses
Biochemical and structural comparisons of non-nucleoside reverse transcriptase inhibitors against feline and human immunodeficiency viruses
- July 20, 2026
- Posted by: Stemskills Lab
Journal of Veterinary Science · 2023 · Cited 2 times
Siriluk Rattanabunyong, Khuanjarat Choengpanya, Chonticha Suwattanasophon, Duangnapa Kiriwan, Peter Wolschann, Thomanai Lamtha, Abdul Rajjak Shaikh, Jatuporn Rattanasrisomporn, Kiattawee Choowongkomon
Feline immunodeficiency virus (FIV) causes an immunodeficiency syndrome in cats with no effective treatment, so this study tested three non-nucleoside reverse transcriptase inhibitors used against HIV, nevirapine, efavirenz, and rilpivirine, on the feline enzyme. Purified feline and human reverse transcriptase were compared using IC50 measurements, surface plasmon resonance binding assays, molecular docking, and molecular dynamics simulations, and all three drugs bound both enzymes with IC50 values in comparable ranges. The authors suggest these drugs could inhibit the feline enzyme too, giving a possible route to treatment for a disease that currently has none.
Learn these methods hands-on
This is the kind of computational work the StemSkills team publishes. Our live Molecular Modeling & MD Simulations cohort teaches you to do it yourself, mentored by published researchers.
See the bootcamp →